Hangzhou Tigermed Consulting Co (FRA:5HZ1) 3-Year RORE % : -61.95% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5HZ1 Hangzhou Tigermed Consulting Co Ltd FRA:5HZ1
87 GF Score
Price €4.08
GF Value €5.05
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hangzhou Tigermed Consulting Co 3-Year RORE %?

Hangzhou Tigermed Consulting Co FRA:5HZ1 -1.45% 87 3-Year RORE % is -61.95 as of Mar. 2026. GuruFocus rates FRA:5HZ1 with a GF Score™ of 87/100 and a GF Value™ of €5.05 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 198 Medical Diagnostics & Research companies, Hangzhou Tigermed Consulting Co ranks worse than 83.84% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Hangzhou Tigermed Consulting Co's 3-Year RORE % for the quarter that ended in Mar. 2026 was -61.95%.

The industry rank for Hangzhou Tigermed Consulting Co's 3-Year RORE % or its related term are showing as below:

FRA:5HZ1's 3-Year RORE % is ranked worse than
83.84% of 198 companies
in the Medical Diagnostics & Research industry
Industry Median: -7.79 vs FRA:5HZ1: -61.95

Hangzhou Tigermed Consulting Co  (FRA:5HZ1) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Hangzhou Tigermed Consulting Co 3-Year RORE % Related Terms


Hangzhou Tigermed Consulting Co 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Hangzhou Tigermed Consulting Co's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Tigermed Consulting Co 3-Year RORE % Chart

Hangzhou Tigermed Consulting Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.18 5.03 -14.52 -56.96 -58.31

Hangzhou Tigermed Consulting Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -68.69 -82.29 -67.96 -58.31 -61.95

FRA:5HZ1 vs TMO, DHR, IDXX: 3-Year RORE % Comparison

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hangzhou Tigermed Consulting Co 3-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's 3-Year RORE % falls into.


FRA:5HZ1
87GF Score
Hangzhou Tigermed Consulting Co Ltd FRA:5HZ1
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hangzhou Tigermed Consulting Co 3-Year RORE % Calculation

Hangzhou Tigermed Consulting Co's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.11-0.25 )/( 0.407-0.181 )
=-0.14/0.226
=-61.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -61.95 mean?
Hangzhou Tigermed Consulting Co (FRA:5HZ1) has a 3-Year RORE % of -61.95 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Hangzhou Tigermed Consulting Co and its competitors. According to the industry distribution chart, Hangzhou Tigermed Consulting Co ranks #166 out of 198 companies in the Medical Diagnostics & Research industry, placing it in the top 83.8%.
Is Hangzhou Tigermed Consulting Co's 3-Year RORE % too high?
Hangzhou Tigermed Consulting Co's current 3-Year RORE % is -61.95. Based on the distribution chart, Hangzhou Tigermed Consulting Co ranks #166 out of 198 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's 3-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Hangzhou Tigermed Consulting Co ranks #166 out of 198 companies for 3-Year RORE %. This places Hangzhou Tigermed Consulting Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Hangzhou Tigermed Consulting Co and its competitors. Hangzhou Tigermed Consulting Co's current 3-Year RORE % is -61.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co (FRA:5HZ1) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.05, compared to a current price of €4.08 — trading 19.2% below its estimated fair value. The current 3-Year RORE % is -61.95. Hangzhou Tigermed Consulting Co's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (FRA:5HZ1), the current 3-Year RORE % is -61.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hangzhou Tigermed Consulting Co (FRA:5HZ1) Overvalued in 2026?

Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued. The current stock price of €4.08 is trading 19.2% below its estimated GF Value™ of €5.05. GuruFocus considers Hangzhou Tigermed Consulting Co to be Modestly Undervalued.

Key valuation signals for FRA:5HZ1:

  • 3-Year RORE %: -61.95
  • GF Value™: €5.05 vs. price of €4.08 (19.2% below fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the FRA:5HZ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hangzhou Tigermed Consulting Co Business Description

Other Exchanges 03347:Hong Kong300347:China
Address No. 508 Lujiatan Street, Room 601-610, 6th Floor, Puyan Sub-District, Binjiang District, Zhejiang Province, Hangzhou, CHN
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
87GF Score

Get the complete analysis for FRA:5HZ1

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€5.05
GF Value